Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Daniel P. Cahill, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Daniel Cahill and Julie Miller.
Connection Strength

5.410
  1. Sirtuin activation targets IDH-mutant tumors. Neuro Oncol. 2021 01 30; 23(1):53-62.
    View in: PubMed
    Score: 0.918
  2. MGMT promoter methylation and hypermutant recurrence in IDH mutant lower-grade glioma. Neuro Oncol. 2020 11 26; 22(11):1553-1554.
    View in: PubMed
    Score: 0.907
  3. Accelerated progression of IDH mutant glioma after first recurrence. Neuro Oncol. 2019 05 06; 21(5):669-677.
    View in: PubMed
    Score: 0.814
  4. Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications. Cancer. 2017 Dec 01; 123(23):4535-4546.
    View in: PubMed
    Score: 0.729
  5. Enhancing demethylation-induced differentiation in IDH-mutant glioma. Neuro Oncol. 2022 Mar 03.
    View in: PubMed
    Score: 0.247
  6. Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD+ to Potentiate the Metabolic Lethality of Alkylating Chemotherapy in IDH-Mutant Tumor Cells. Cancer Discov. 2020 11; 10(11):1672-1689.
    View in: PubMed
    Score: 0.220
  7. PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. Clin Cancer Res. 2019 07 15; 25(14):4375-4387.
    View in: PubMed
    Score: 0.203
  8. Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups. J Neurooncol. 2019 Jan; 141(2):327-335.
    View in: PubMed
    Score: 0.198
  9. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations. Acta Neuropathol Commun. 2018 10 17; 6(1):106.
    View in: PubMed
    Score: 0.196
  10. Genotype-targeted local therapy of glioma. Proc Natl Acad Sci U S A. 2018 09 04; 115(36):E8388-E8394.
    View in: PubMed
    Score: 0.193
  11. Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas. Oncotarget. 2017 Dec 12; 8(65):109228-109237.
    View in: PubMed
    Score: 0.184
  12. The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity. Cancer Res. 2017 08 01; 77(15):4102-4115.
    View in: PubMed
    Score: 0.179
  13. Perspectives on investigational drugs and immunotherapies for glioblastoma. Expert Opin Investig Drugs. 2016 Sep; 25(9):1007-9.
    View in: PubMed
    Score: 0.169
  14. A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma. Cancer Res. 2020 12 01; 80(23):5330-5343.
    View in: PubMed
    Score: 0.056
  15. IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice. Oncoimmunology. 2020 08 20; 9(1):1806662.
    View in: PubMed
    Score: 0.056
  16. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide. Mol Cancer Ther. 2018 12; 17(12):2551-2563.
    View in: PubMed
    Score: 0.049
  17. DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathol. 2018 11; 136(5):779-792.
    View in: PubMed
    Score: 0.048
  18. Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. NPJ Precis Oncol. 2017; 1(1):5.
    View in: PubMed
    Score: 0.044
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.